Mescaline

Mescaline (3,4,5-trimethoxyphenethylamine) is a naturally occurring classical psychedelic of the phenethylamine family. It is the principal active alkaloid of several ritual cacti — most famously Peyote (Lophophora williamsii) and San Pedro (Echinopsis pachanoi / Trichocereus pachanoi), together with the related Peruvian Torch (Echinopsis peruviana) and Bolivian Torch (Echinopsis lageniformis). Peyote and San Pedro have been used by indigenous peoples of the Americas for at least 5,700 years, making mescaline-bearing cacti among the oldest documented entheogens on Earth.

Mescaline was first isolated by the German chemist Arthur Heffter in 1897 and first synthesised by Ernst Späth in 1919 — the first psychedelic to be chemically characterised. Aldous Huxley popularised it in Western culture with The Doors of Perception (1954), and Alexander Shulgin catalogued it as the reference molecule for the entire phenethylamine class in PiHKAL (1991).

Chemistry

Mescaline is the 3,4,5-trimethoxy analogue of phenethylamine. Molecular formula C₁₁H₁₇NO₃, molar mass 211.26 g/mol. It is the structural backbone from which the entire 2C-x, DOx and scaline families are derived. In nature it co-occurs with a range of related tetrahydroisoquinoline and phenethylamine alkaloids — pellotine, anhalonidine, anhalamine, hordenine and tyramine — which contribute to the subtly different character of whole-cactus experiences compared with pure synthetic mescaline HCl.

Content varies widely by species, specimen, age and growing conditions. Dried Peyote buttons typically contain 1–6% mescaline by dry weight, while dried San Pedro flesh contains roughly 0.3–2%. Green cactus is about 90% water, so fresh-weight doses are 5–10× the dry-weight figure.

Pharmacology

Mescaline is a partial agonist at the 5-HT2A, 5-HT2C and 5-HT1A receptors, with 5-HT2A activation considered the primary driver of psychedelic effects. Compared with LSD or psilocin it is a far weaker receptor binder on a per-molecule basis — which is why active doses sit in the hundreds of milligrams rather than micrograms.

It is orally bioavailable, largely metabolised by monoamine oxidase (MAO) and by O-demethylation in the liver, and excreted mostly unchanged in urine. Its long half-life (≈6 hours) combined with slow CNS clearance explains the characteristic 10–14 hour trajectory. Unlike amphetamines it has only weak affinity for the dopamine and noradrenaline transporters, though some stimulation is noted at higher doses.

Effects

Typical subjective effects, emerging progressively from roughly 45–90 minutes after oral dosing:

• Visual — drifting, flowing, kaleidoscopic open- and closed-eye imagery; strong colour saturation; geometric patterning often described as "warm", "organic" or "living"
• Cognitive — conceptual thinking amplification, philosophical introspection, ego softening, emotional openness and a pronounced sense of interconnectedness; less "alien" than DMT and less "machine-like" than LSD
• Somatic — body-wide warmth, mild-to-moderate stimulation, muscle tension, mild tachycardia and elevated blood pressure
• Sensory — enhanced music appreciation, synaesthesia at higher doses, taste and smell intensification
• Experiential — many users describe mescaline as notably earthy, embodied and heart-centred compared with other classical psychedelics

Nausea is extremely common — especially in the first 1–3 hours and especially with whole-cactus material, which contains bitter non-psychoactive alkaloids. Purging is traditional in ceremonial contexts and many users report it as part of the psychological "clearing" of the experience.

Harm Reduction

• Nausea management: fast for 6+ hours beforehand; consider ginger tea, small amounts of honey, or low-dose ondansetron (with medical advice) for cactus preparations.
• Cardiovascular load: mescaline produces sustained mild-to-moderate increases in heart rate and blood pressure; people with cardiac disease, uncontrolled hypertension or a history of arrhythmia should avoid it.
• Contraindicated combinations: MAOIs (including harmala alkaloids in ayahuasca admixtures), lithium (seizure and neurotoxicity risk), tramadol (seizure threshold), high-dose SSRIs/SNRIs (serotonin syndrome risk, though most SSRIs blunt rather than amplify effects).
• Mental-health screening: personal or first-degree-family history of schizophrenia, bipolar I or other psychotic disorders is a strong contraindication. HPPD is rare but documented.
• Misidentification risk: mescaline is rarely found adulterated because synthesis is low-yield and expensive, but blotters and powders sold as "mescaline" are frequently 2C-B, DOx (DOB/DOC/DOI) or NBOMe compounds, which are active in the low milligram to microgram range and substantially more dangerous. Weigh everything; use reagent tests.
• Driving and machinery: mescaline impairs judgement, reaction time and coordination for the full duration plus several hours of aftereffects.

Related Compounds

• Peyote (Lophophora williamsii) — slow-growing button cactus, 1–6% mescaline, culturally central to the Native American Church
• San Pedro / Huachuma (Echinopsis pachanoi) — fast-growing Andean columnar cactus, 0.3–2% mescaline, widespread in ceremonial and neo-shamanic use
• Peruvian Torch (Echinopsis peruviana) — similar columnar cactus, often higher mescaline content than San Pedro
• Bolivian Torch (Echinopsis lageniformis) — another columnar species used as a mescaline source
• Pellotine, anhalonidine, anhalamine — co-occurring cactus alkaloids with mild sedative/bitter character
• 2C-x family (2C-B, 2C-E, 2C-I …) — ring-substituted phenethylamines structurally derived from mescaline, most documented in Shulgin’s PiHKAL
• DOx family (DOB, DOC, DOI) — α-methylated analogues, far more potent and much longer-lasting
• Escaline, proscaline, allylescaline — "scaline" homologues with variable potency and character